Continuous Purification of IL-12/IL-15 Albumin-Binding Domain Fusion Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cytokines such as IL-12 and IL-15 have short circulatory half-lives and are prone to proteolytic degradation during manufacturing, leading to frequent dosing requirements and potential toxicity, while their therapeutic potential is hindered by proteolytic enzymes and protein aggregation.
Innovation Solution
A method for producing IL-12/IL-15 albumin binding domain fusion proteins involves direct connection of a bioreactor to a purification system with chromatography columns, minimizing exposure to proteolytic enzymes by continuous purification, thereby reducing degradation and enabling high yield production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cytokines are produced using conventional manufacturing methods with separation between bioreactor and purification system, then production yield is reduced due to proteolytic degradation, but direct connection increases system complexity
Solution Approach 1:
The patent merges the bioreactor and purification system into a directly connected integrated system, eliminating intermediate transfer steps. This allows continuous purification of cytokines as they are produced, preventing proteolytic degradation while maintaining high production yield through streamlined processing
2Reliability
If cytokines are administered frequently to maintain therapeutic levels, then therapeutic efficacy is improved, but toxicity increases due to repeated administration
Solution Approach 1:
The patent changes the molecular parameter of the cytokine by fusing it with an albumin binding domain. This structural modification enables the cytokine to bind to albumin and utilize the FcRn recycling pathway, extending its circulatory half-life from hours to days, thereby reducing dosing frequency and cumulative toxicity while maintaining therapeutic efficacy
3Stability of the object's composition
If cytokines are purified after production, then proteolytic degradation is reduced, but exposure time to proteolytic enzymes increases
Solution Approach 1:
The patent implements preliminary purification action by directly connecting the purification system to the bioreactor. This allows purification to begin immediately as cytokines are produced, minimizing exposure time to proteolytic enzymes before the cytokines can be degraded
4Duration of action of stationary object
If albumin binding domain is fused to cytokine, then circulatory half-life is extended, but manufacturing complexity increases
Solution Approach 1:
The patent employs a universal albumin binding domain that can be fused to various cytokines to extend their half-lives. This modular approach uses a standardized binding domain that interacts with the universal albumin-FcRn pathway, allowing the same structural solution to be applied across different cytokine therapies without requiring cytokine-specific modifications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in less degraded IL-12/IL-15 albumin binding domain fusion proteins with extended half-lives, reducing the need for frequent dosing and minimizing toxicity, while maintaining therapeutic efficacy.
Implementation Method 1
Albumin binds to the FcRn in a pH-dependent manner in the acidic environment of the early endosome. Albumin-FcRn binding diverts albumin molecules from degradation in the lysosomal compartment and redirects the albumin molecules to the plasma membrane, where they are released back into the blood plasma due to the neutral pH.
Implementation Method 2
A method for producing IL-12/IL-15 albumin binding domain fusion proteins involves direct connection of a bioreactor to a purification system with chromatography columns, minimizing exposure to proteolytic enzymes by continuous purification
Data Source
AI summary
Provided herein are methods for making recombinant IL-12/IL-15 albumin binding domain (ABD) fusion proteins. The subject methods advantageously include a continuous downstream purification step that leads to high yield production of purified cytokine-based proteins.